ImmuCell reports Q2 2026 results, expands capacity plans
ImmuCell reported second-quarter product sales of $7.2 million, net income of $1.8 million and gross margin of 33.9%, while planning $8 million in capacity investments.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.